At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GENB Generate Biomedicines
Trading 10-16 11:10:36 EDT
12.53
-0.53
-4.06%
High13.22Low12.42Vol190.11K
Open13.02D1 Closing13.06Amplitude6.13%
Mkt Cap1.61BTradable Cap755.41MTotal Shares128.19M
T/O2.41MT/O Rate0.32%Tradable Shares60.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
TIPRANKS  ·  10-14 04:40
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Zealand Pharma Partners with Generate Biomedicines on AI-Designed Protein Therapeutics for Metabolic Diseases
Reuters  ·  10-14 04:31
Zealand Pharma Partners with Generate Biomedicines on AI-Designed Protein Therapeutics for Metabolic Diseases
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
THOMSON REUTERS  ·  10-14 04:30
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines - to Receive $30 Mln Upfront, up to $1.20 Bln in Milestones, Plus Royalties
THOMSON REUTERS  ·  10-14 04:30
Generate Biomedicines - to Receive $30 Mln Upfront, up to $1.20 Bln in Milestones, Plus Royalties
Generate Biomedicines - Co to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
THOMSON REUTERS  ·  10-14 04:30
Generate Biomedicines - Co to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
Generate Biomedicines - to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
THOMSON REUTERS  ·  10-14 04:30
Generate Biomedicines - to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
Zealand Pharma, Generate Strike Obesity Drug Deal Worth up to $1.2 Billion, Bloomberg News Reports
Reuters  ·  10-14 04:27
Zealand Pharma, Generate Strike Obesity Drug Deal Worth up to $1.2 Billion, Bloomberg News Reports
Zealand Pharma Makes Deal with Generate Worth up to $1.2 Billion - Bloomberg News
THOMSON REUTERS  ·  10-14 04:13
Zealand Pharma Makes Deal with Generate Worth up to $1.2 Billion - Bloomberg News
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-05
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Seven new option listings on October 2nd
TIPRANKS  ·  10-02
Seven new option listings on October 2nd
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
TIPRANKS  ·  10-02
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
Generate Biomedicines - Gb-5267 Targets Muc16 Biomarker in over 80% of Ovarian Tumors
THOMSON REUTERS  ·  10-01
Generate Biomedicines - Gb-5267 Targets Muc16 Biomarker in over 80% of Ovarian Tumors
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ Car T Therapy for Ovarian Cancer
THOMSON REUTERS  ·  10-01
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ Car T Therapy for Ovarian Cancer
Generate Biomedicines - Gb-5267 Treatment Designed to Avoid Pre-Infusion Chemotherapy
THOMSON REUTERS  ·  10-01
Generate Biomedicines - Gb-5267 Treatment Designed to Avoid Pre-Infusion Chemotherapy
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-09
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Generate Biomedicines Management to Present at Upcoming Investor Conferences
Reuters  ·  09-08
Generate Biomedicines Management to Present at Upcoming Investor Conferences
Generate Biomedicines Director Frances Arnold Sells USD 16,002 of Common Shares
Reuters  ·  09-04
Generate Biomedicines Director Frances Arnold Sells USD 16,002 of Common Shares
Generate Biomedicines is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  08-28
Generate Biomedicines is Maintained at Buy by HC Wainwright & Co.
U.S. Research Roundup-Dollar General, Palo Alto, Workday
Reuters  ·  08-28
U.S. Research Roundup-Dollar General, Palo Alto, Workday
Small U.S. Stocks Finish Mixed as Abercrombie & Fitch Leads, Generate Biomedicines Lags
Dow Jones  ·  08-27
Small U.S. Stocks Finish Mixed as Abercrombie & Fitch Leads, Generate Biomedicines Lags

Introduction

Company Name.
Generate Biomedicines
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Generate Biomedicines, Inc. was incorporated in August 2018 under Delaware law. As a clinical-stage generative biology company, it pioneered an AI-driven biotechnology platform called the Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology candidates into Phase 1 trials by 2026.
Issue price:
--